
Join to view full profile
2711 Randolph RdSte 400Charlotte, NC 28207
Phone+1 704-342-1900
Fax+1 704-377-0353
Dr. Shehadeh is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2001 - 2004
Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1997
Jordan University of Science and Technology FOMClass of 1992
Certifications & Licensure
CA State Medical License 2006 - 2027
NC State Medical License 2015 - 2027
SC State Medical License 2022 - 2027
OH State Medical License 2009 - 2022
MI State Medical License 1996 - 2018
FL State Medical License 2009 - 2017
MN State Medical License 1997 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2014, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2017
Clinical Trials
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Publications & Presentations
PubMed
- 38 citationsPhase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.Arkadiusz Z. Dudek, K. Lesniewski-Kmak, N. J. Shehadeh, O. N. Pandey, Michael J Franklin
British Journal of Cancer. 2009-05-05 - 23 citationsBenefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neckNasfat J. Shehadeh, John F. Ensley, Omer Kucuk, Carri Black, George H. Yoo
Head & Neck. 2006-12-01 - 12 citationsAn in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma.George H. Yoo, Geetha Subramanian, Ramesh R. Boinpally, Andrew J. Iskander, Nasfat Shehadeh
Archives of Otolaryngology--Head & Neck Surgery. 2005-05-01
Press Mentions
Disease Disappears for All Patients in Clinical Trial Study for Rectal CancerAugust 8th, 2022
Featured Practice: Oncology Specialists of CharlotteJune 18th, 2021
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
